The presence of circulating anti-nuclear antibodies (ANAs) is a hallmark of immune dysregulation in patients with systemic sclerosis (SSc). Currently, a variety of SSc-specific ANAs, including anticentromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies, have been well characterized, and their commercial kits are available worldwide. Since these autoantibodies are specifically detected in SSc patients and are associated with unique sets of disease manifestations, they are widely used in routine clinical practice for diagnosis, clinical subgrouping, and prediction of future organ involvements and prognosis. In addition, SSc-specific ANAs are also useful in predicting future development of SSc in patients with Raynaud's phenomenon without any scleroderma skin changes, because their production often precedes onset of SSc symptoms. Application of circulating SSc-specific ANA measurement to clinical practice has greatly improved patient care, but utility of the autoantibody testing could be maximized by combining other clinical information, such as degree and extent of skin thickness and disease duration. (J Nippon Med Sch 2017; 84: 56 63) 
Introduction
Systemic sclerosis (SSc) or scleroderma is a connective tissue disease characterized by excessive fibrosis, microangiopathy, and immune dysregulation, including autoimmunity and chronic low-grade inflammation 1 .
Multiple genes contribute to disease susceptibility, but environmental exposures are likely to play a major role in causing and progressing the disease. Since clinical presentation in patients with SSc is highly variable, disease subgrouping as well as prediction of future organ involvement and prognosis are extremely important in clinical setting. One of the distinctive hallmarks of the immune dysregulation is the presence of circulating autoantibodies reactive with various cellular components.
The majority of disease-associated autoantibodies in SSc patients are anti-nuclear antibodies (ANAs) that target proteins that play essential roles in transcription, splicing, and cell division. It has been shown that ANA specificities specifically detected in SSc patients are associated with unique disease manifestations. Therefore, individual ANAs are attractive biomarkers in routine rheumatology practice. This review features the spectrum of SSc-specific ANAs and their clinical utility.
SSc-specific and SSc-related ANAs
ANAs detected by indirect immunofluorescence (IIF) technique are a hallmark of SSc, and are found in >95% of the patients. The majority of nuclear autoantigens recognized by SSc sera have been already identified to date.
ANAs detected in SSc sera can be divided into two groups, including SSc-specific ANAs, which are specifically detected in SSc patients, and SSc-associated ANAs, which are found in patients with SSc but also in those with non-SSc connective tissue diseases. Currently, at least 10 ANA specificities specific to SSc have been reported and well characterized. These include anticentromere, anti-topoisomerase I (topo I), anti-RNA polymerase (RNAP) III, anti-U3 ribonucleoprotein (RNP), anti-Th/To, anti-U11/U12 RNP, anti-PM-Scl, anti-Ku, anti-RuvBL1/2, anti-U1 RNP antibodies. These SSc-specific ANAs are detectable in >80% of SSc patients. Two classic autoantibodies discovered in the late 1970's are anti-topo 
Anti-topoisomerase I (Topo I) Antibody
Anti-topo I antibody was first discovered by double immunodiffusion assay as an antibody reactive with a 70-kDa protein (Scl-70) 10 , which was later identified as an enzyme that catalyzes relaxation of supercoiled doublestranded DNA, termed topo I 11 . Anti-topo I antibody is detected in 20 30% of SSc patients in many ethnic groups, and is highly specific to SSc. The coexistence of anti-topo I and other SSc-related ANAs is rare ( 1%). Almost two-thirds of anti-topo I-positive patients have diffuse cutaneous SSc (dcSSc), but progression of skin thickening is slower than those with anti-RNAP III antibody 12 . 16, 17 . Age at onset is older and the proportion of males tends to be higher in patients with anti-RNAP III. Nearly all patients with this antibody have dcSSc with rapidly progressive skin thickening. Despite that, many patients experience rapid regression of skin thickening over time even without treatment.
Patients with anti-RNAP III antibody have the highest risk for developing SRC, but they seldom develop severe ILD 13 . In Northern Europe and North America, approximately 60% of all patients experiencing SRC carry anti-RNAP III antibody 18 The temporal relationship between cancer and SSc among anti-RNAP III-positive patients suggests that SSc is a para-neoplastic disorder in this patient subset 26 .
Anti-U3 RNP Antibody
Anti-U3 RNP antibody was first identified by RNA-IP assay as an autoantibody that precipitated the U3 RNP particle, which consists of 34-kD fibrillarin complexed with U3 RNA 27 . This antibody produces bright nucleolar staining on IIF. Anti-U3 RNP antibody is found in 4 10% of patients with SSc, and is the most frequent in African Americans 28 . Two thirds of the patients have dcSSc, but others are classified as typical lcSSc. Nearly one-third of the patients develop non-inflammatory skeletal myopathy, which is an SSc-related condition distinct from myositis overlap. It has been reported that severe GI involvement, including pseudo-obstruction and small bowel malabsorption, is associated with anti-U3 RNP antibody, especially in early course of the disease (<2 years) 29 . Severe internal organ involvement, including ILD, PAH, cardiomyopathy, and SRC are common in pa-tients with anti-U3 RNP antibody, irrespective of dcSSc or lcSSc. Anti-U3 RNP antibody was identified as an independent risk factor for development of PAH in the large case-control study 30 . In fact, PAH is the most common cause of death, leading to an increased mortality in this group of patients 28 . An unusual combination of SRC followed later by PAH is occasionally found in patients with dcSSc and anti-U3 RNP antibody 31 . Survival in anti-U3 RNP-positive patients is comparable to that in patients with anti-topo I antibody.
Anti-Th/To Antibody
Anti-Th/To antibody was identified by RNA-IP assay as an antibody that precipitated both 7-2 and 8-2 RNAs.
Later, it has been shown that this antibody directs against subunits of mitochondrial RNA processing and ribonuclease P complexes 32 . Of at least 6 subunits consisting of these complexes, a 120-kDa protein contains the major autoantibody epitope 33 Anti-PM-Scl antibody produces a homogenous nucleolar pattern, and is rarely found in non-Caucasian patients 36 .
Anti-PM-Scl-positive patients often present with the subacute myositis, but also have typical Raynaud's phenomenon and scleroderma skin changes, usually lcSSc 37 .
They are most frequently diagnosed as having SScpolymyositis (PM) overlap, but a significant proportion of the patients have rashes consistent with dermatomyositis (DM). This antibody is found in more than 25% of SSc patients with myositis overlap, but in only 2% of SSc patients overall. Serious internal organ involvement is rare, leading to a favorable prognosis. Myositis is usually mild and shows a good response to corticosteroids.
In a recent large cross-sectional study of patients with idiopathic inflammatory myopathies, 9% had anti-PM-Scl antibody in the absence of any scleroderma skin changes 38 . Anti-U1 RNP antibody was first described as a serologic marker for mixed connective tissue disease (MCTD) 43 
Disease Subsetting
Classification of patients into dcSSc and lcSSc subsets is useful in predicting future organ involvement and prognosis, but more precise subgrouping is feasible by considering SSc-specific ANAs because of their strong correlations with main organ manifestations ( Table 1) .
For example, three major dcSSc-specific ANAs, including anti-topo I, anti-RNAP III, and anti-U3 RNP antibodies, cover >80% of dcSSc patients, but major organ involvements linking to poor prognosis are apparently different.
The presence of anti-topo I antibody in dcSSc patients provides independent prognostic information with regard to a risk for progression of ILD and a greater risk of mortality 8 . In contrast, anti-RNAP III antibody has also been associated with increased mortality, primarily due to an increased prevalence of SRC 8 , but with improvement in the management of SRC, such associations may not be replicated in the future. On the other hand, PAH still remains intractable condition with poor long-term survival even after introduction of a series of pulmonary vasodilators, and can occur in dcSSc patients with anti-U3 RNP antibody.
In addition, it is often difficult to classify patients into dcSSc or lcSSc early in the course of the disease when skin thickness is restricted to the distal portion of extremities. In this case, information on SSc-specific ANAs is useful in predicting the future extent of skin involvement. If one of dcSSc-associated ANAs, including antitopo I, anti-RNAP III, and anti-U3 RNP antibodies, is present in circulation, disease modifying treatment should be indicated for preventing future organ damage at an early stage of dcSSc.
Conclusions
In summary, circulating ANA specificities are the best biomarkers for diagnosis and clinical subgrouping of SSc patients. Characterization of autoantibody status is an essential tool in clinical practice in the evaluation of patients who have SSc or are suspected to have this disease. In addition, because of their strong clinical associations, they allow clinicians to predict future disease manifestations and help to decide treatment strategy in individual patients. It is important to note, however, that clinical associations of autoantibodies are not absolute, and organ-specific manifestations can occur in the presence of any autoantibody reactivity.
